Edad gestacional neonatal y patrones de crecimiento en niños menores de 24 meses atendidos en el Policlínico Policial de Huancayo, Junín-2019

En la actualidad la edad infantil constituye el periodo más trascendente en la vida del ser humano, la marca por completo. De la calidad sanitaria, nutricional, psicológica y educativa en la que el niño se desarrolle va a depender en gran parte su calidad de vida en la edad adulta. Todos estos factores siguen siendo de gran importancia en la adolescencia y los primeros años del adulto joven (1). Los niños representan el futuro, y su crecimiento y desarrollo saludable deben ser una de las máximas prioridades para todas las sociedades. Los niños y los recién nacidos en particular son especialmente vulnerables frente a la malnutrición y enfermedades infecciosas, que son prevenibles o tratables en su mayoría (OMS, 2019). Durante los primeros años de vida, y en particular desde el embarazo hasta los 3 años, los niños necesitan nutrición, protección y estimulación para que su cerebro se desarrolle correctamente. Los progresos recientes en el campo de la neurociencia aportan nuevos datos sobre el desarrollo cerebral durante esta etapa de la vida. Gracias a ellos, sabemos que en los primeros años, el cerebro de los bebés forma nuevas conexiones a una velocidad asombrosa (3)

1er workshop nacional: de investigación en la formación inicial de profesores de ciencias “reflexiones de la investigación formativa en ciencias mediada por contextos tecnológicos”

La vereda el Pensil del municipio de la Argentina, Huila, Colombia se caracteriza por sus cultivos de café, sin embargo, en estos habitan organismos como las serpientes y los murciélagos de los cuales se desconoce el valor biológico que tienen estos individuos y como consecuencia de esto atentan contra ellos destruyendo el equilibrio ecológico del ecosistema. Teniendo en cuenta lo anterior se planteó como objetivo de investigación generar conciencia ambiental a través de una experiencia significativa sobre la importancia biológica de los quirópteros y serpientes El proyecto de investigación se desarrolló a partir de guías por parte los estudiantes los cuales indagaron concepciones en torno a las serpientes y murciélagos, donde se conoció la visión de la comunidad acerca del papel ecológico que cumplen. Se evidenció el desconocimiento por parte de la comunidad pues se observa que el mayor porcentaje de personas no conocen la función de controladores de plagas de ambos organismos o las funciones polinizadoras y dispersoras de semillas de los murciélagos. En conclusión, la falta de educación ambiental puede llevar a que la comunidad genere desequilibrio biológico y atente contra especies que les genera cierto temor y que están rodeadas de mitos productos del conocimiento popular

I simposio Internacional sobre Investigación en la enseñanza de las ciencias

Edición 202

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols

Proceedings Of The 23Rd Paediatric Rheumatology European Society Congress: Part Two

PubMe

Evaluation of a quality improvement intervention to reduce anastomotic leak following right colectomy (EAGLE): pragmatic, batched stepped-wedge, cluster-randomized trial in 64 countries

Background Anastomotic leak affects 8 per cent of patients after right colectomy with a 10-fold increased risk of postoperative death. The EAGLE study aimed to develop and test whether an international, standardized quality improvement intervention could reduce anastomotic leaks. Methods The internationally intended protocol, iteratively co-developed by a multistage Delphi process, comprised an online educational module introducing risk stratification, an intraoperative checklist, and harmonized surgical techniques. Clusters (hospital teams) were randomized to one of three arms with varied sequences of intervention/data collection by a derived stepped-wedge batch design (at least 18 hospital teams per batch). Patients were blinded to the study allocation. Low- and middle-income country enrolment was encouraged. The primary outcome (assessed by intention to treat) was anastomotic leak rate, and subgroup analyses by module completion (at least 80 per cent of surgeons, high engagement; less than 50 per cent, low engagement) were preplanned. Results A total 355 hospital teams registered, with 332 from 64 countries (39.2 per cent low and middle income) included in the final analysis. The online modules were completed by half of the surgeons (2143 of 4411). The primary analysis included 3039 of the 3268 patients recruited (206 patients had no anastomosis and 23 were lost to follow-up), with anastomotic leaks arising before and after the intervention in 10.1 and 9.6 per cent respectively (adjusted OR 0.87, 95 per cent c.i. 0.59 to 1.30; P = 0.498). The proportion of surgeons completing the educational modules was an influence: the leak rate decreased from 12.2 per cent (61 of 500) before intervention to 5.1 per cent (24 of 473) after intervention in high-engagement centres (adjusted OR 0.36, 0.20 to 0.64; P < 0.001), but this was not observed in low-engagement hospitals (8.3 per cent (59 of 714) and 13.8 per cent (61 of 443) respectively; adjusted OR 2.09, 1.31 to 3.31). Conclusion Completion of globally available digital training by engaged teams can alter anastomotic leak rates. Registration number: NCT04270721 (http://www.clinicaltrials.gov)